Merit Medical Systems has acquired Solo Pace for approximately $45 million, adding temporary pacing technology designed for transcatheter heart valve procedures to its Cardiac Therapies platform. Merit acquired all remaining outstanding equity in Minneapolis-based Solo Pace on October 13, 2026.
The transaction follows a prior relationship between the companies in which Merit invested in Solo Pace and served as the exclusive distributor of its precision intraprocedural pacing technology. Between January 2023 and December 2025, Merit paid a total of $5 million to acquire approximately 18% of Solo Pace, obtain an option to acquire the remaining equity based on commercialization milestones, and secure exclusive distribution rights.
Solo Pace develops temporary pacing technology for procedures including transcatheter aortic valve replacement, or TAVR. The acquisition adds the SOLO PACE CONTROL and SOLO PACE FUSION systems to Merit's portfolio. TAVR is a minimally invasive procedure used to replace the aortic valve in patients with aortic stenosis. More than 100,000 TAVR procedures are performed annually in the U.S. Temporary pacing is an important element of the procedure because it supports accurate valve deployment.
SOLO PACE FUSION is a sterile, single-use system combining guidewire functionality, left ventricular pacing, and patient grounding within one device. It is designed to work with the SOLO PACE CONTROL external pulse generator and includes features such as automated pace capture checks, sterile remote operation, visual indicators, and support for operator-specific protocols. Solo Pace received FDA 510(k) clearance for SOLO PACE FUSION in April 2025 and commercially launched the system in March 2026.
Merit expects the acquisition to have an immaterial effect on its previously forecasted 2026 financial performance. For 2027, the transaction is expected to be slightly accretive to non-GAAP net income and earnings per share, while being slightly dilutive on a GAAP basis before becoming accretive thereafter.
"This acquisition expands our Cardiac Therapies platform and further strengthens our position in the structural heart market," said Martha G. Aronson, President and Chief Executive Officer of Merit Medical Systems. David V. Daniels, Interventional Cardiologist and Founder of Solo Pace, said the SOLO PACE CONTROL and FUSION systems "have the potential to redefine pacing in transcatheter valve procedures."